Literature DB >> 14519144

Expression of cysteinyl leukotriene synthetic and signalling proteins in inflammatory cells in active seasonal allergic rhinitis.

D J Figueroa1, L Borish, D Baramki, G Philip, C P Austin, J F Evans.   

Abstract

BACKGROUND: Cysteinyl leukotrienes (CysLTs) are bioactive lipids that have been shown to contribute to allergic and inflammatory diseases. Eosinophils and mast cells have the capacity to produce large amounts of CysLTs after allergic or non-allergic stimulation. Molecular identification of both the synthetic and signalling proteins in the CysLT pathway allows the investigation of expression of the CysLT enzymes and receptors in active allergic rhinitis.
OBJECTIVE: We examined the expression of the proteins involved in the synthesis of CysLTs and the cysteinyl leukotriene-1 (CysLT1) and cysteinyl leukotriene-2 (CysLT2) receptors in inflammatory cells from patients with active seasonal allergic rhinitis.
METHODS: Nasal lavage samples were obtained from patients during active seasonal allergic rhinitis. Specific cellular immunocytochemical techniques were used to detect the cysteinyl leukotriene synthetic proteins, namely 5-lipoxygenase (5-LO), 5-lipoxygenase-activating protein (FLAP) and leukotriene C4 synthase (LTC4S). In situ hybridization and immunocytochemical techniques were used to identify the mRNA and proteins for the CysLT1 and CysLT2 receptors.
RESULTS: 5-LO, FLAP and LTC4S, and the CysLT1 and CysLT2 receptors were expressed in the majority of eosinophils and in subsets of mast cells and mononuclear cells. 5-LO, FLAP and the CysLT1 receptor, but not LTC4S or the CysLT2 receptor, were expressed in a subset of nasal neutrophils.
CONCLUSIONS: Our study demonstrates the presence of CysLT pathway proteins in key allergic and inflammatory cells from the upper airway of patients with active seasonal allergic rhinitis. Our expression data highlight the potential of CysLT-modifying agents to treat both upper and lower airway symptoms in patients suffering from allergic rhinitis and asthma.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14519144     DOI: 10.1046/j.1365-2222.2003.01786.x

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  36 in total

1.  Genetic deletion of 5-lipoxygenase increases tumor-infiltrating macrophages in Apc(Δ468) mice.

Authors:  Eric C Cheon; Matthew J Strouch; Seth B Krantz; Michael J Heiferman; David J Bentrem
Journal:  J Gastrointest Surg       Date:  2011-11-10       Impact factor: 3.452

2.  Leukotriene Inhibitors in Sinusitis.

Authors:  John W Steinke; Joshua L Kennedy
Journal:  Curr Infect Dis Rep       Date:  2012-01-29       Impact factor: 3.725

3.  Concordant modulation of cysteinyl leukotriene receptor expression by IL-4 and IFN-gamma on peripheral immune cells.

Authors:  S Brandon Early; Elizabeth Barekzi; Julie Negri; Kathleen Hise; Larry Borish; John W Steinke
Journal:  Am J Respir Cell Mol Biol       Date:  2007-02-01       Impact factor: 6.914

4.  GPR17 is a negative regulator of the cysteinyl leukotriene 1 receptor response to leukotriene D4.

Authors:  Akiko Maekawa; Barbara Balestrieri; K Frank Austen; Yoshihide Kanaoka
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-26       Impact factor: 11.205

5.  Biological effects of leukotriene E4 on eosinophils.

Authors:  John W Steinke; Julie Negri; Spencer C Payne; Larry Borish
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2014-03-26       Impact factor: 4.006

6.  Discovery of Highly Potent Dual CysLT1 and CysLT2 Antagonist.

Authors:  Satoshi Itadani; Shinya Takahashi; Masaki Ima; Tetsuya Sekiguchi; Manabu Fujita; Yoshisuke Nakayama; Jun Takeuchi
Journal:  ACS Med Chem Lett       Date:  2014-10-06       Impact factor: 4.345

7.  GPR17 regulates immune pulmonary inflammation induced by house dust mites.

Authors:  Akiko Maekawa; Wei Xing; K Frank Austen; Yoshihide Kanaoka
Journal:  J Immunol       Date:  2010-06-23       Impact factor: 5.422

Review 8.  Antileukotrienes in upper airway inflammatory diseases.

Authors:  Cemal Cingi; Nuray Bayar Muluk; Kagan Ipci; Ethem Şahin
Journal:  Curr Allergy Asthma Rep       Date:  2015-11       Impact factor: 4.806

9.  Cysteinyl leukotriene 1 receptor controls the severity of chronic pulmonary inflammation and fibrosis.

Authors:  Thomas C Beller; Daniel S Friend; Akiko Maekawa; Bing K Lam; K Frank Austen; Yoshihide Kanaoka
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-17       Impact factor: 11.205

10.  Variable expression of cysteinyl leukotriene type I receptor splice variants in asthmatic females with different promoter haplotypes.

Authors:  Milena Sokolowska; Karolina Wodz-Naskiewicz; Malgorzata Cieslak; Karolina Seta; Andrzej K Bednarek; Rafal Pawliczak
Journal:  BMC Immunol       Date:  2009-12-15       Impact factor: 3.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.